Infinity Pharmaceuticals, Inc. (INFI) financial statements (2021 and earlier)

Company profile

Business Address 1100 MASSACHUSETTS AVENUE
CAMBRIDGE, MA 02138
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments34414350425263
Cash and cash equivalents29192930222243
Short-term investments6231420203020
Restricted cash and investments00     
Prepaid expense2222221
Other current assets0001001
Total current assets:36434553455465
Noncurrent Assets
Operating lease, right-of-use asset1122222
Property, plant and equipment2222221
Restricted cash and investments0000000
Other noncurrent assets0000000
Total noncurrent assets:3344453
TOTAL ASSETS:39474957495968
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities114431058
Accounts payable3111221
Accrued liabilities8111817
Employee-related liabilities 221 2 
Debt   0 0 
Other undisclosed current liabilities 655 4 
Total current liabilities:1110981098
Noncurrent Liabilities
Long-term debt and lease obligation1222222
Operating lease, liability1222222
Liabilities, other than long-term debt0100000
Other liabilities0100000
Other undisclosed noncurrent liabilities50494949303029
Total noncurrent liabilities:51515151323231
Total liabilities:62616059414039
Stockholders' equity
Stockholders' equity attributable to parent(23)(14)(11)(2)81930
Common stock0000000
Additional paid in capital743742735734733733733
Accumulated other comprehensive income (loss)(0)000000
Accumulated deficit(766)(756)(746)(737)(726)(714)(703)
Total stockholders' equity:(23)(14)(11)(2)81930
TOTAL LIABILITIES AND EQUITY:39474957495968

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gross profit:0000000
Operating expenses(11)(9)(9)(11)(12)(11)(10)
Operating loss:(10)(9)(9)(11)(12)(11)(10)
Nonoperating income (expense)(0)(1)(1)(0)0(1)(1)
Other nonoperating income (expense)0(0)00 00
Interest and debt expense(0)(0)(0)(0)(0)(1)(1)
Other undisclosed income from continuing operations before equity method investments, income taxes0000011
Net loss available to common stockholders, diluted:(11)(10)(9)(11)(11)(11)(11)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(11)(10)(9)(11)(11)(11)(11)
Comprehensive loss:(11)(10)(9)(11)(11)(11)(11)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)(0)0(0)(0)0
Comprehensive loss, net of tax, attributable to parent:(11)(10)(10)(11)(11)(11)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: